Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Punekar, S. R.; Hong, D. S.; Luo, J.; Ou, S. H. I.; Johnson, M. L.; Spira, A.; Garrido-Laguna, I.; Goldman, J. W.; Herzberg, B.; Saltos, A.; Mitra, P.; Hegde, A.; Vora, R.; Hiremath, M.; Arbour, K. C. |
| Abstract Title: | Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC) |
| Meeting Title: | European Lung Cancer Congress (ELCC) 2025 |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 20 |
| Issue: | 3 Suppl. 1 |
| Meeting Dates: | 2025 Mar 26-29 |
| Meeting Location: | Paris, France |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2025-03-01 |
| Start Page: | S10 |
| End Page: | S11 |
| Language: | English |
| ACCESSION: | WOS:001469780300009 |
| PROVIDER: | wos |
| DOI: | 10.1016/s1556-0864(25)00201-1 |
| Notes: | Meeting Abstract: 6MO -- Source: Wos |
